GALT
What one share of Galectin Therapeutics holds
Pharmaceutical Preparations
We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions.
Galectin Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.43 |
|---|---|
| Cash and investments | $0.20 |
| Book value | −$2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$0.93 | — | −$0.51 | — | −$0.16 |
| 2011 | — | −$1.06 | $0.00 | −$0.47 | — | −$0.16 |
| 2012 | — | −$0.72 | $0.00 | −$0.50 | — | $0.07 |
| 2013 | — | −$1.30 | $0.00 | −$0.44 | — | $0.08 |
| 2014 | — | −$0.78 | $0.00 | −$0.57 | — | $0.95 |
| 2015 | — | −$0.88 | $0.00 | −$0.70 | — | $0.63 |
| 2016 | — | −$0.77 | — | −$0.56 | — | $0.31 |
| 2017 | — | −$0.49 | — | −$0.45 | — | −$0.01 |
| 2018 | — | −$0.38 | — | −$0.26 | — | $0.13 |
| 2019 | — | −$0.39 | — | −$0.21 | — | $0.77 |
| 2020 | — | −$0.41 | — | −$0.36 | — | $0.39 |
| 2021 | — | −$0.52 | — | −$0.42 | — | $0.01 |
| 2022 | — | −$0.65 | — | −$0.52 | — | −$0.57 |
| 2023 | — | −$0.74 | — | −$0.55 | — | −$1.00 |
| 2024 | — | −$0.76 | — | −$0.67 | — | −$1.66 |
| 2025 | — | −$0.48 | — | −$0.37 | — | −$1.96 |